Unknown PHASE1 INTERVENTIONAL 1-arm NCT05508620

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

A Phase Ib Study to Evaluate the Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Malignant Solid Tumors With TSC1/2 Genetic Alterations

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions Malignant Solid Tumors

Interventions Sirolimus for Injection (Albumin-bound)

Updated 4 times since 2022 Last updated: Aug 19, 2022 Started: Oct 31, 2022 Primary completion: Dec 31, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05508620, this PHASE1 trial focuses on Malignant Solid Tumors and remains ongoing. Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., it has been updated 4 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE1

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1
Sep 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Data source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.